



## **FLASH**

### **Cardio3 BioSciences Presents C-Cure® Phase II Clinical Trial Results at the EuroPCR Meeting**

#### **Innovative Heart-Specified Stem Cell Therapy Opens a New Chapter in Cardiovascular Regenerative Medicine**

**Mont-Saint-Guibert, Belgium, May 16, 2011** – The Belgian biotechnology company, Cardio3 BioSciences, a leader in discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, will present Phase II clinical trial data of the flagship product C3BS-CQR-1 (C-Cure®), at the EuroPCR Meeting in Paris on Wednesday, 18<sup>th</sup> May. This is the First-in-man use of lineage specified stem cells for the treatment of heart failure.

On behalf of the C-Cure international program, data will be presented by Dr. Dariouch Dolatabadi, Civil Hospital, Charleroi, Belgium and Investigator of the C3BS-CQR-1 (C-Cure) trial.

The trial demonstrates that heart failure patients improved heart function and exercise capacity at 6 months following treatment of C-Cure, an innovative stem cell therapy based on the Company's "Cardiopoiesis" proprietary technology. Moreover, feasibility and safety of the C-Cure treatment regimen were established.

Data strongly suggest that C-Cure is a promising treatment for heart failure, one of the world's greatest unmet medical needs. A person living to the age of 40 has a one-in-five risk of developing heart failure and, once the disorder is apparent, a one-in-three chances of dying within a year of diagnosis.

More detailed information on [www.c3bs.com/fr/products-pipeline/clinical.html](http://www.c3bs.com/fr/products-pipeline/clinical.html)

**\*\*\* END \*\*\***

For more information contact:

**Cardio3 BioSciences**

Dr. Christian Homsy, CEO

Anne Portzenheim, Communication Manager

Tel: +32 10 39 41 00

[aportzenheim@c3bs.com](mailto:aportzenheim@c3bs.com)

**Citigate Dewe Rogerson**

Chris Gardner/Nina Enegren

Tel : +44 (0) 207 638 9571

[chris.gardner@citigatedr.co.uk](mailto:chris.gardner@citigatedr.co.uk)

**Hill & Knowlton**

Katia Delvaille

Tel : +32 2 737 95 00

[kdelvail@hillandknowlton.com](mailto:kdelvail@hillandknowlton.com)

CARDIO3 BIOSCIENCES S.A.

Axisparc Business Center – Rue Edouard Belin 12 – 1435 Mont-Saint-Guibert – Belgium  
Tel +32 (10) 39 41 00 – Fax +32 (10) 39 41 41 – Email [info@c3bs.com](mailto:info@c3bs.com) – [www.c3bs.com](http://www.c3bs.com)